Biosafe Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-06-2024
- Paid Up Capital ₹ 0.10 M
as on 23-06-2024
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.50 M
as on 23-06-2024
- Revenue 39.86%
(FY 2022)
- Profit 64.97%
(FY 2022)
- Ebitda 78.24%
(FY 2022)
- Net Worth 100.33%
(FY 2022)
- Total Assets 4.79%
(FY 2022)
About Biosafe Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.50 M.
Vivek Sharma, Santosh Singh, and Sunil Mishra serve as directors at the Company.
- CIN/LLPIN
U52311MH2010PTC202132
- Company No.
202132
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Apr 2010
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Biosafe Pharmaceuticals Private Limited offer?
Biosafe Pharmaceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Hair Growth Medicine, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Dog Bones, Bath Soaps, Ketoconazole Soap, Skin Lightening Drugs, Glutathione Tablet, Vitamins & Supplements.
Who are the key members and board of directors at Biosafe Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vivek Sharma  | Director | 17-Apr-2010 | Current |
| Santosh Singh | Director | 03-Jan-2014 | Current |
| Sunil Mishra | Director | 17-Apr-2010 | Current |
Financial Performance of Biosafe Pharmaceuticals.
Biosafe Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 39.86% increase. The company also saw a substantial improvement in profitability, with a 64.97% increase in profit. The company's net worth Soared by an impressive increase of 100.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biosafe Pharmaceuticals?
In 2021, Biosafe Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Sep 2023 | ₹2.50 M | Open |
How Many Employees Work at Biosafe Pharmaceuticals?
Unlock and access historical data on people associated with Biosafe Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biosafe Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biosafe Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
